Prospects for pirarubicin.
Miller
A A
AA
Department of Medicine, University of Tennessee, Memphis 38163.
Salewski
E
E
D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008654:Mesothelioma / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; C027260:pirarubicin